Regulators accused Martin Shkreli of violating a lifetime ban on pharmaceutical industry activity and sought penalties including divestment of his biopharma stock holdings.

What it means

Martin Shkreli, the former pharmaceutical executive known as 'Pharma Bro,' is facing new legal trouble. Regulators from the Federal Trade Commission (FTC) and seven states have accused him of violating a lifetime ban on participating in the pharmaceutical industry, which was imposed after his earlier antitrust violations. The allegation centers on his trading of biopharma stocks, which he reportedly livestreamed, and regulators are seeking penalties including the forced sale of his holdings.

Accuracy & sourcesGrounded

The claim is solidly based on a formal complaint filed by the FTC and state attorneys general, as reported by multiple reputable outlets including MarketWatch, Bloomberg, and Ars Technica. The reporting sits close to the primary source—the legal filing—and the allegations are clearly stated, though they have not yet been adjudicated.

How new

This is genuinely new coverage, published on October 13, 2026, and not a resurfacing of older material.

Go deeper